155 related articles for article (PubMed ID: 19963035)
1. Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease.
Todoerti K; Lisignoli G; Storti P; Agnelli L; Novara F; Manferdini C; Codeluppi K; Colla S; Crugnola M; Abeltino M; Bolzoni M; Sgobba V; Facchini A; Lambertenghi-Deliliers G; Zuffardi O; Rizzoli V; Neri A; Giuliani N
Exp Hematol; 2010 Feb; 38(2):141-53. PubMed ID: 19963035
[TBL] [Abstract][Full Text] [Related]
2. Myeloma and Bone Disease.
Panaroni C; Yee AJ; Raje NS
Curr Osteoporos Rep; 2017 Oct; 15(5):483-498. PubMed ID: 28861842
[TBL] [Abstract][Full Text] [Related]
3. A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function.
Vallet S; Pozzi S; Patel K; Vaghela N; Fulciniti MT; Veiby P; Hideshima T; Santo L; Cirstea D; Scadden DT; Anderson KC; Raje N
Leukemia; 2011 Jul; 25(7):1174-81. PubMed ID: 21403648
[TBL] [Abstract][Full Text] [Related]
4. An Evidence-Based Approach to Myeloma Bone Disease.
Bingham N; Reale A; Spencer A
Curr Hematol Malig Rep; 2017 Apr; 12(2):109-118. PubMed ID: 28243849
[TBL] [Abstract][Full Text] [Related]
5. CC-chemokine ligand 20/macrophage inflammatory protein-3α and CC-chemokine receptor 6 are overexpressed in myeloma microenvironment related to osteolytic bone lesions.
Giuliani N; Lisignoli G; Colla S; Lazzaretti M; Storti P; Mancini C; Bonomini S; Manferdini C; Codeluppi K; Facchini A; Rizzoli V
Cancer Res; 2008 Aug; 68(16):6840-50. PubMed ID: 18703490
[TBL] [Abstract][Full Text] [Related]
6. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma.
Tian E; Zhan F; Walker R; Rasmussen E; Ma Y; Barlogie B; Shaughnessy JD
N Engl J Med; 2003 Dec; 349(26):2483-94. PubMed ID: 14695408
[TBL] [Abstract][Full Text] [Related]
7. Hepatocyte growth factor (HGF) induces interleukin-11 secretion from osteoblasts: a possible role for HGF in myeloma-associated osteolytic bone disease.
Hjertner O; Torgersen ML; Seidel C; Hjorth-Hansen H; Waage A; Børset M; Sundan A
Blood; 1999 Dec; 94(11):3883-8. PubMed ID: 10572104
[TBL] [Abstract][Full Text] [Related]
8. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
Kupisiewicz K
Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
[TBL] [Abstract][Full Text] [Related]
9. Bone osteoblastic and mesenchymal stromal cells lack primarily tumoral features in multiple myeloma patients.
Giuliani N; Lisignoli G; Novara F; Storti P; Zaffaroni N; Villa R; Sammarelli G; Agnelli L; Todoerti K; Bernardo ME; Manferdini C; Colla S; Abeltino M; Bolzoni M; Rocci A; Gabusi E; Palumbo A; Zuffardi O; Neri A; Rizzoli V
Leukemia; 2010 Jul; 24(7):1368-70. PubMed ID: 20485369
[No Abstract] [Full Text] [Related]
10. Myeloma cell-induced disruption of bone remodelling compartments leads to osteolytic lesions and generation of osteoclast-myeloma hybrid cells.
Andersen TL; Søe K; Sondergaard TE; Plesner T; Delaisse JM
Br J Haematol; 2010 Feb; 148(4):551-61. PubMed ID: 19919653
[TBL] [Abstract][Full Text] [Related]
11. Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition.
Giuliani N; Rizzoli V; Roodman GD
Blood; 2006 Dec; 108(13):3992-6. PubMed ID: 16917004
[TBL] [Abstract][Full Text] [Related]
12. Impaired osteoblastogenesis in myeloma bone disease: role of upregulated apoptosis by cytokines and malignant plasma cells.
Silvestris F; Cafforio P; Calvani N; Dammacco F
Br J Haematol; 2004 Aug; 126(4):475-86. PubMed ID: 15287939
[TBL] [Abstract][Full Text] [Related]
13. The bone marrow stromal compartment in multiple myeloma patients retains capability for osteogenic differentiation in vitro: defining the stromal defect in myeloma.
Kassen D; Moore S; Percy L; Herledan G; Bounds D; Rodriguez-Justo M; Croucher P; Yong K
Br J Haematol; 2014 Oct; 167(2):194-206. PubMed ID: 25079197
[TBL] [Abstract][Full Text] [Related]
14. The multiple myeloma bone eco-system and its relation to oncogenesis.
Bataille R
Morphologie; 2015 Jun; 99(325):31-7. PubMed ID: 26005000
[TBL] [Abstract][Full Text] [Related]
15. A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma.
Gunn WG; Conley A; Deininger L; Olson SD; Prockop DJ; Gregory CA
Stem Cells; 2006 Apr; 24(4):986-91. PubMed ID: 16293576
[TBL] [Abstract][Full Text] [Related]
16. Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells.
Bolzoni M; Donofrio G; Storti P; Guasco D; Toscani D; Lazzaretti M; Bonomini S; Agnelli L; Capocefalo A; Dalla Palma B; Neri A; Nicolini F; Lisignoli G; Russo F; Colla S; Aversa F; Giuliani N
Leukemia; 2013 Feb; 27(2):451-63. PubMed ID: 22781592
[TBL] [Abstract][Full Text] [Related]
17. Myeloma and bone disease: "the dangerous tango".
Epstein J; Walker R
Clin Adv Hematol Oncol; 2006 Apr; 4(4):300-6. PubMed ID: 16728940
[TBL] [Abstract][Full Text] [Related]
18. Transcriptome Analysis of Mesenchymal Stem Cells from Multiple Myeloma Patients Reveals Downregulation of Genes Involved in Cell Cycle Progression, Immune Response, and Bone Metabolism.
Fernando RC; Mazzotti DR; Azevedo H; Sandes AF; Rizzatti EG; de Oliveira MB; Alves VLF; Eugênio AIP; de Carvalho F; Dalboni MA; Martins DC; Colleoni GWB
Sci Rep; 2019 Jan; 9(1):1056. PubMed ID: 30705326
[TBL] [Abstract][Full Text] [Related]
19. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.
Heath DJ; Chantry AD; Buckle CH; Coulton L; Shaughnessy JD; Evans HR; Snowden JA; Stover DR; Vanderkerken K; Croucher PI
J Bone Miner Res; 2009 Mar; 24(3):425-36. PubMed ID: 19016584
[TBL] [Abstract][Full Text] [Related]
20. Multiple myeloma and bone.
Chappard D
Morphologie; 2015 Jun; 99(325):29-30. PubMed ID: 25952499
[No Abstract] [Full Text] [Related]
[Next] [New Search]
